The Tisch Cancer Institute

Innovation and transformation energize our programs and reflect The Tisch Cancer Institute’s world-class research. We are a National Cancer Institute-designated Cancer Center and have joined an elite group of U.S. institutions committed to the research and treatment of cancer. 

This specialty report highlights:

  • Mount Sinai’s Human Immune Monitoring Core (HIMC), which actively works with clinicians to help characterize the cellular and molecular immune profiles of tumor lesions in their patients
  • Our Vaccine and Cell Therapy Laboratory, which supports the development and manufacturing of novel vaccines and cell-based therapies for cancer and infectious diseases
  • Novel research into therapies that improve the standard of care for patients who develop acute graft-versus-host disease (GVHD) following bone-marrow transplantation
  • Pioneering research collaborations with Celgene and three leading U.S. academic institutions
  • Young researchers who bring insights from physics, mathematics, and genomics